A detailed history of Geode Capital Management, LLC transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Geode Capital Management, LLC holds 428,270 shares of LGND stock, worth $49.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
428,270
Previous 405,775 5.54%
Holding current value
$49.1 Million
Previous $34.2 Million 25.47%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$82.7 - $110.11 $1.86 Million - $2.48 Million
22,495 Added 5.54%
428,270 $42.9 Million
Q2 2024

Aug 09, 2024

BUY
$68.53 - $87.91 $1.7 Million - $2.18 Million
24,805 Added 6.51%
405,775 $34.2 Million
Q1 2024

May 13, 2024

BUY
$68.64 - $89.2 $697,039 - $905,826
10,155 Added 2.74%
380,970 $27.8 Million
Q4 2023

Feb 13, 2024

BUY
$49.57 - $72.63 $901,876 - $1.32 Million
18,194 Added 5.16%
370,815 $26.5 Million
Q3 2023

Nov 13, 2023

BUY
$58.86 - $72.67 $647,930 - $799,951
11,008 Added 3.22%
352,621 $21.1 Million
Q2 2023

Aug 11, 2023

BUY
$69.53 - $79.33 $1.73 Million - $1.97 Million
24,814 Added 7.83%
341,613 $24.6 Million
Q1 2023

May 15, 2023

BUY
$65.67 - $77.08 $1.06 Million - $1.24 Million
16,129 Added 5.36%
316,799 $23.3 Million
Q4 2022

Feb 13, 2023

BUY
$61.72 - $96.74 $651,763 - $1.02 Million
10,560 Added 3.64%
300,670 $20.1 Million
Q3 2022

Nov 14, 2022

SELL
$0.01 - $107.56 $6 - $66,149
-615 Reduced 0.21%
290,110 $25 Million
Q2 2022

Aug 12, 2022

SELL
$74.52 - $117.06 $735,661 - $1.16 Million
-9,872 Reduced 3.28%
290,725 $25.9 Million
Q1 2022

May 13, 2022

BUY
$94.99 - $151.56 $1.51 Million - $2.41 Million
15,934 Added 5.6%
300,597 $33.8 Million
Q4 2021

Feb 11, 2022

BUY
$127.69 - $165.85 $1.1 Million - $1.43 Million
8,648 Added 3.13%
284,663 $44 Million
Q3 2021

Nov 12, 2021

SELL
$102.33 - $144.73 $158,099 - $223,607
-1,545 Reduced 0.56%
276,015 $38.5 Million
Q2 2021

Aug 13, 2021

BUY
$113.03 - $155.64 $1.66 Million - $2.29 Million
14,684 Added 5.59%
277,560 $36.4 Million
Q1 2021

May 12, 2021

BUY
$99.52 - $215.83 $2.89 Million - $6.27 Million
29,069 Added 12.43%
262,876 $40.1 Million
Q4 2020

Feb 12, 2021

BUY
$80.55 - $106.05 $158,764 - $209,024
1,971 Added 0.85%
233,807 $23.3 Million
Q3 2020

Nov 13, 2020

SELL
$89.56 - $126.72 $810,249 - $1.15 Million
-9,047 Reduced 3.76%
231,836 $22.1 Million
Q2 2020

Aug 13, 2020

SELL
$68.28 - $123.65 $1.29 Million - $2.34 Million
-18,940 Reduced 7.29%
240,883 $26.9 Million
Q1 2020

May 14, 2020

BUY
$63.37 - $107.88 $628,440 - $1.07 Million
9,917 Added 3.97%
259,823 $18.9 Million
Q4 2019

Feb 13, 2020

SELL
$96.94 - $113.59 $735,677 - $862,034
-7,589 Reduced 2.95%
249,906 $26.1 Million
Q3 2019

Nov 12, 2019

SELL
$86.25 - $120.16 $411,585 - $573,403
-4,772 Reduced 1.82%
257,495 $25.6 Million
Q2 2019

Aug 14, 2019

BUY
$107.38 - $129.34 $270,490 - $325,807
2,519 Added 0.97%
262,267 $29.9 Million
Q1 2019

May 14, 2019

BUY
$105.93 - $142.47 $1.2 Million - $1.61 Million
11,288 Added 4.54%
259,748 $32.7 Million
Q4 2018

Feb 13, 2019

BUY
$128.36 - $272.13 $2.67 Million - $5.65 Million
20,769 Added 9.12%
248,460 $33.7 Million
Q3 2018

Nov 13, 2018

BUY
$211.18 - $274.49 $1.49 Million - $1.94 Million
7,054 Added 3.2%
227,691 $62.5 Million
Q2 2018

Aug 14, 2018

BUY
$150.77 - $207.98 $3.42 Million - $4.72 Million
22,710 Added 11.47%
220,637 $45.7 Million
Q1 2018

May 15, 2018

BUY
$138.63 - $182.62 $1.07 Million - $1.41 Million
7,741 Added 4.07%
197,927 $32.7 Million
Q4 2017

Feb 13, 2018

BUY
$128.36 - $147.04 $1.28 Million - $1.47 Million
10,006 Added 5.55%
190,186 $26 Million
Q3 2017

Nov 14, 2017

BUY
$120.91 - $137.94 $232,389 - $265,120
1,922 Added 1.08%
180,180 $24.5 Million
Q2 2017

Aug 14, 2017

BUY
N/A
178,258
178,258 $21.6 Million

Others Institutions Holding LGND

About LIGAND PHARMACEUTICALS INC


  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $1.94B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.